983-20970-92954
3 vaccinations
5 coded responses
8 check-ins
5 free-text entries
3 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 852 / AZ
- Registered
- 2021-02-26
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-27
Dose 1 — Pfizer-BioNTech
-
2021-01-20
Dose 2 — Pfizer-BioNTech
-
2021-02-26
Registered in v-safe
- 2021-02-26
- 2021-03-03
- 2021-04-21
-
2021-07-21
Survey response — 6 months, dose 2MedDRA: Migraine, Self-medication — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Break through migraine yesterday (7/20), treated with my usual medication.MedDRA releases: 2024-11 · check-in free text available
-
2021-11-29
Dose 3 — Pfizer-BioNTech
-
2022-01-20
Survey response — 12 months, dose 2MedDRA: Hypertension, Office visit — Feeling: Fair · Get care from a doctor or other healthcare professionalFree text: Symptoms: Hypertension · Healthcare visit (other): In person pcp visitMedDRA releases: 2024-11 · check-in free text available
-
2022-01-20
Report sent to call center — 12 months, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2022-01-21
-
2022-02-28
Survey response — 3 months, dose 3MedDRA: Haemorrhagic ovarian cyst, Hypertension, Immune system disorder, Office visit — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Symptoms: Hemorrhagic ovarian cyst, new onset hypertension, moderate immune reaction to the booster · Healthcare visit (other): Discovered htn at routine pcp visitMedDRA releases: 2024-11 · check-in free text available
-
2022-02-28
Report sent to call center — 3 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-03-17
-
2022-05-30
Survey response — 6 months, dose 3MedDRA: Adenomyosis, Adhesiolysis, Endometriosis, Hysterectomy, Pre-existing disease, Salpingo-oophorectomy unilateral, Surgery — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, HospitalizationFree text: Symptoms: Poorly controled prior htn. New: Endometrioma requiring total hysterectomy with left salpingoophorectomy and lysis of extensive adhesions. Dx w/ silent extensive endomeriosis, pathology also showed asymptomatic adenomyosis · Healthcare visit (other): SurgeryMedDRA releases: 2024-11 · check-in free text available
-
2022-05-30
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · Hospitalization · 1 call case(s)
-
2022-06-01
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2022-06-01
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2022-06-01
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2022-12-01
Survey response — 12 months, dose 3MedDRA: Glucose tolerance impaired, Glycosylated haemoglobin increased — Feeling: GoodFree text: Increased A1C, pre-diabeticMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-27 | Pfizer-BioNTech | |
| 2 | 2021-01-20 | Pfizer-BioNTech | |
| 3 | 2021-11-29 | Pfizer-BioNTech | No |
Call center
3 call center cases
3 successful
Free text
Release 9 — 6 months, dose 2
Symptoms: Break through migraine yesterday (7/20), treated with my usual medication.
Release 10 — 12 months, dose 2
Release 11 — 3 months, dose 3
Symptoms: Hemorrhagic ovarian cyst, new onset hypertension, moderate immune reaction to the booster
Healthcare visit (other): Discovered htn at routine pcp visit
Release 11 — 6 months, dose 3
Symptoms: Poorly controled prior htn. New: Endometrioma requiring total hysterectomy with left salpingoophorectomy and lysis of extensive adhesions. Dx w/ silent extensive endomeriosis, pathology also showed asymptomatic adenomyosis
Healthcare visit (other): Surgery
Release 12 — 12 months, dose 3
Symptoms: Increased A1C, pre-diabetic
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Hypertension | · | · | ✓ |
| HCVO | Office visit | · | · | ✓ |
| HCVO | Surgery | · | · | ✓ |
| SD | Adenomyosis | · | · | ✓ |
| SD | Adhesiolysis | · | · | ✓ |
| SD | Endometriosis | · | · | ✓ |
| SD | Glucose tolerance impaired | · | · | ✓ |
| SD | Glycosylated haemoglobin increased | · | · | ✓ |
| SD | Haemorrhagic ovarian cyst | · | · | ✓ |
| SD | Hypertension | · | · | ✓ |
| SD | Hysterectomy | · | · | ✓ |
| SD | Immune system disorder | · | · | ✓ |
| SD | Migraine | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
| SD | Salpingo-oophorectomy unilateral | · | · | ✓ |
| SD | Self-medication | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release